ALKS
ALKS
Positions held
Your positionsALKS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)
2026-09-30 · LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
2026-09-26 · Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
2026-09-23 · Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290
2026-09-22 · Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says
2026-09-22 · Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
2026-09-22 · An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
2026-09-21 · How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
2026-09-21 · Sector Update: Healthcare Stocks Mixed Premarket Monday
2026-09-21 · Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell
2026-09-21 · Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290
Price (daily)
Full chart · RSI · MACD · patterns